At the effective time of the merger, each outstanding ordinary share of Kadimastem will be exchanged for a specified number of fully paid and nonassessable common shares of NLS Pharmaceutics, as ...
In addition, NLS Pharmaceutics provided unaudited pro forma condensed combined financial statements for the six months ended June 30, 2025. According to the previously announced merger agreement, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results